In-vivo antidiabetic activity of asparagus racemosus seeds in streptozotocin induced diabetic model

Anubhav Dubey*, Mamta Kumari, Vimal Kumar

Department of Pharmacology, Maharana Pratap College of Pharmacy, Kanpur, Uttar Pradesh, India

Refer this article

Anubhav Dubey, Mamta Kumari, Vimal Kumar. In vivo antidiabetic activity of asparagus racemosus seeds in streptozotocin induced diabetic model. May-June 2024, V2 – I3, Pages - 0146 – 0152. Doi: https://doi.org/10.55522/ijti.V2I3.0037.

ABSTRACT

The point of this study was to find out how well the methanolic seed extract of Asparagus racemosus treated diabetes in rats that had been given streptozotocin (STZ). We administered a single intraperitoneal injection of STZ (65 mg/kg) to the experimental animal to achieve the desired effect. We divided a group of adult male Wister albino rats into five groups: normal control, diabetic control, diabetic glibenclamide (5 mg/kg), diabetic methanolic seed extract of Asparagus racemosus (200 mg/kg), and diabetic methanolic seed extract of Asparagus racemosus extract (400 mg/kg). We observed these rats for 14 days to measure their body weight (BW) and blood glucose levels. The STZ-treated diabetic rats showed a significant increase in blood glucose levels and a concurrent decrease in body weight. The study involved administering methanolic seed extracts of Asparagus racemosus (at doses of 200 and 400 mg/kg) and glibenclamide (at a dose of 5 mg/kg) orally to rats for a period of 14 days. The results indicated a substantial decrease in blood glucose levels and an increase in body weight compared to both the control group and the group treated with glibenclamide. The study revealed that the seed component of the Asparagus racemosus methanolic extract had a strong antidiabetic effect.

Keywords:

Diabetes mellitus, Methaolic extract, Glibenclamide, Blood glucose, Streptozotocin.